Physician profile
Mark S Rubin
NPI 1033192570
$8,771.31
in general payments reported to CMS, 2019-2025
70 companies · $687 in 2025
The $687 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $2,096 · 2021: $1,245 · 2022: $2,398 · 2023: $878 · 2024: $783 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurobindo Pharma USA, INC. | $1,664.06 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $1,303.46 | 2020-2023 | Enhertu |
| Janssen Biotech, INC. | $559.14 | 2019-2025 | Rybrevant, Tecvayli, Darzalex |
| Celgene Corporation | $323.66 | 2020-2025 | Reblozyl |
| Genzyme Corporation | $320.86 | 2019-2025 | |
| Incyte Corporation | $308.19 | 2020-2025 | Pemazyre, Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $273.30 | 2020-2025 | Enhertu, Datroway |
| Abbvie INC. | $255.41 | 2019-2025 | |
| Merz North America, INC. | $249.30 | 2021-2022 | |
| Tesaro, INC. | $228.38 | 2019 | |
| Merck Sharp & Dohme LLC | $215.98 | 2020-2025 | Keytruda, Lynparza |
| Astellas Pharma US INC | $195.53 | 2021-2025 | Xospata, Padcev, Vyloy |
| Sirtex Medical INC | $167.82 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $148.99 | 2019-2024 | Tavalisse, Rezlidhia |
| Glaxosmithkline, LLC. | $140.03 | 2022-2025 | Jemperli, Zejula, Shingrix |
Show all 69 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,740,788.93 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.